Today, Lexicon announced an exclusive licensing agreement with Novo Nordisk to further develop our investigational ACSL5 inhibitor in obesity and associated metabolic disorders. This agreement underscores the potential of our pipeline to address unmet needs and positions us to strategically expand our R&D and clinical development efforts.???? ??? Learn more via our press release at: https://lnkd.in/gB3q5CNA
Lexicon Pharmaceuticals, Inc.
制药业
The Woodlands，TX 21,440 位关注者
At Lexicon, We Pioneer Medicines that Transform Patients' Lives
关于我们
Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. A Diverse Pipeline of Targeted Therapies Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
- 网站
-
https://www.lexpharma.com/
Lexicon Pharmaceuticals, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 51-200 人
- 总部
- The Woodlands，TX
- 类型
- 上市公司
- 创立
- 1995
- 领域
- biopharma、knockout、novel drug、innovation、disease和pharmaceutical
地点
Lexicon Pharmaceuticals, Inc.员工
-
Paul Chen
Executive Leadership: Global Market Access | Payer Relations | Managed Markets | Channel & Distribution Strategies
-
Paul Monville
-
Frank Palantoni
Investor, New Ventures
-
Melinda (Thiel) Francini
Vice President, Commercial Strategy & Innovation | Pacesetting health care executive with expertise across the healthcare ecosystem
动态
-
We are continuing to raise awareness of DPNP, a debilitating condition which can significantly disrupt everyday life for patients. Nearly 60% of those living with DPNP have tried multiple treatments, and only a third are satisfied with their treatment plan. With limited advances in care over the past two decades, there is an urgent need for new treatment options.
-
-
DPNP is a highly prevalent and chronic condition that significantly impacts quality of life, affecting an estimated 9 million people in the United States. At Lexicon, we are committed to improving outcomes for people living with DPNP, raising awareness about the severity of DPNP and advancing the treatment landscape to help patients achieve better pain control.
-
-
Tomorrow is International Women’s Day, a global celebration to honor the remarkable achievements and contributions of women all over the world. At Lexicon, we are proud to support and empower women across our organization, as well as through our external partnerships, as we work to #AccelerateAction and break barriers to pave the way for future generations and ensure a more inclusive and equitable world for all.? Join us in celebrating #InternationalWomensDay as we highlight the incredible clinical investigators we work with as they share their experiences as women working in healthcare.? #IWD2025?
-
Lexicon Pharmaceuticals reports our fourth quarter 2024 financial results and provides a business update. ? To view the full press release, visit: https://lnkd.in/gP9Ygzxz
-
-
Yesterday, Lexicon reported topline results from our Phase 2b PROGRESS study evaluating our investigational non-opioid DPNP therapy. We’re pleased to share that we achieved our objective to find an appropriate dose to advance into Phase 3 development. Learn more: https://lnkd.in/gAbdeikP
-
-
The Lancet Diabetes & Endocrinology has published research we previously presented at the #ASH24 Annual Meeting. The paper highlights the benefits of our SGLT1/SGLT2 inhibitor in reducing Major Adverse Cardiovascular Events (MACE). Read more:?https://bit.ly/4hYuL3I
-
-
February is American Heart Month—a time to spotlight heart health and support those affected by heart disease. At Lexicon, we're dedicated to improving care for cardiometabolic conditions like hypertrophic cardiomyopathy (HCM), a genetic heart disorder characterized by the thickening of the left ventricle which limits how much blood the ventricle can take in and pump out with each heartbeat. There are an estimated 1.1 million people?living with HCM in the United States.
-